AstraZeneca's Vaxzevria Gets Full Marketing Authorization in EU for Prevention of Covid-19
01 Novembre 2022 - 08:41AM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Tuesday that its Covid-19 vaccine Vaxzevria
has been granted full marketing authorization in the European
Union.
The Anglo-Swedish pharmaceutical giant said Vaxzevria has been
shown to be effective against all forms of Covid-19.
"The move from conditional to full marketing authorization for
Vaxzevria is an important confirmation by the EMA of the safety and
efficacy of Vaxzevria, demonstrating that the benefits continue to
outweigh the potential risks," Iskra Reic, executive vice
president, vaccines and immune therapies at AstraZeneca, said.
Vaxzevria was originally granted conditional marketing
authorization due to the urgency of the Covid-19 pandemic, it
said.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
November 01, 2022 03:26 ET (07:26 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2023 a Mar 2024